The global aneurysmal subarachnoid hemorrhage drugs market size was valued at $323.51 million in 2020, and is projected to reach $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030. Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the area around the brain. The major factors that drive the growth of the global aSAH drugs market include surge in geriatric population and increase in population suffering from hypertension. Furthermore, lifestyle changes such as alcohol consumption and smoking increase risk of aSAH, which, in turn, propel the market growth.

[COVIDIMPACTSTATEMENT]

Get more information on this report : Request Sample Pages

Hypertension is one of the major factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70.0 million American adults suffer from high blood pressure, of which the condition of only 52.0% is under control. Moreover, according to the Centers for Medicare and Medicaid Services the U.S. healthcare expenditures grew from 4.6% to $3.8 trillion in 2019 and accounted for 17.7% of gross domestic product (GDP). In addition, the federal government accounted for 29 % of total health expenditures, followed by households with 28.4%. State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

Furthermore, incidence of high blood pressure has increased, costing the U.S. $46.0 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.

In addition, increase in prevalence diseases such as stroke and hypertension and surge in geriatric population drive the growth of the aSAH drugs market. In addition, lifestyle changes, including increase in alcohol consumption and smoking rise the risk for aSAH, which, in turn, stimulates the market growth.

However, the associated side effects of drugs and medication taken during the treatment of aSAH restrain the aSAH drugs market share.

The aSAH drugs market is segmented on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

[DRUGCLASSGRAPH]

Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market growth.

[REGIONGRAPH]

Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies, contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increased demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the demand for product. Moreover, China is expected to grow at high CAGR in, thereby making Asia-Pacific a aSAH drugs market opportunity.

The major companies profiled in this report include Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current aSAH drugs market trends, estimations, and dynamics of the aneurysmal subarachnoid hemorrhage drugs market analysis from 2020 to 2030 to identify the prevailing aneurysmal subarachnoid hemorrhage drugs market opportunities.
• The aSAH Drugs Market analysis research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the aneurysmal subarachnoid hemorrhage drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

• The report includes the analysis of the regional as well as global aSAH drugs industry trends, key players, market segments, application areas, and market growth strategies.

 Key Market Segments

• By Drug Class
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agents/Diuretics
  • Other Drugs
  • Opioid Analgesic
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • South Africa
    • Rest of LAMEA

 
Key Market Players

• teva pharmaceutical industries ltd.
• Johnson and Johnson
• Sun Pharmaceutical Industries Ltd.
• NeurOp
• Azurity Pharmaceuticals
• Vitrais, Inc
• Pharmaxis, Ltd.
• orexo ab
• Pfizer, Inc.
• medicure

• CHAPTER 1:INTRODUCTION

  • 1.1.Report description

  • 1.2.Key market segments

  • 1.3.Key benefits to the stakeholders

  • 1.4.Research Methodology

    • 1.4.1.Secondary research

    • 1.4.2.Primary research

    • 1.4.3.Analyst tools and models

• CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study

  • 2.2.CXO Perspective

• CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope

  • 3.2.Key findings

    • 3.2.1.Top investment pockets

  • 3.3.Porter’s five forces analysis

  • 3.4.Top player positioning

  • 3.5.Market dynamics

    • 3.5.1.Drivers

    • 3.5.2.Restraints

    • 3.5.3.Opportunities

  • 3.6.COVID-19 Impact Analysis on the market

• CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS

  • 4.1 Overview

  • 4.1.1 Market size and forecast

  • 4.2 Opioid Analgesic

    • 4.2.1 Key market trends, growth factors and opportunities

    • 4.2.2 Market size and forecast, by region

    • 4.2.3 Market analysis by country

  • 4.3 Calcium Channel Blocker

    • 4.3.1 Key market trends, growth factors and opportunities

    • 4.3.2 Market size and forecast, by region

    • 4.3.3 Market analysis by country

  • 4.4 Anticonvulsant

    • 4.4.1 Key market trends, growth factors and opportunities

    • 4.4.2 Market size and forecast, by region

    • 4.4.3 Market analysis by country

  • 4.5 Stool Softener

    • 4.5.1 Key market trends, growth factors and opportunities

    • 4.5.2 Market size and forecast, by region

    • 4.5.3 Market analysis by country

  • 4.6 Osmotic Agents/Diuretics

    • 4.6.1 Key market trends, growth factors and opportunities

    • 4.6.2 Market size and forecast, by region

    • 4.6.3 Market analysis by country

  • 4.7 Other Drugs

    • 4.7.1 Key market trends, growth factors and opportunities

    • 4.7.2 Market size and forecast, by region

    • 4.7.3 Market analysis by country

• CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION

  • 5.1 Overview

  • 5.1.1 Market size and forecast

  • 5.2 North America

    • 5.2.1 Key trends and opportunities

    • 5.2.2 North America Market size and forecast, by Drug Class

    • 5.2.3 North America Market size and forecast, by country

      • 5.2.3.1 U.S.

      • 5.2.3.1.1 Market size and forecast, by Drug Class

      • 5.2.3.2 Canada

      • 5.2.3.2.1 Market size and forecast, by Drug Class

      • 5.2.3.3 Mexico

      • 5.2.3.3.1 Market size and forecast, by Drug Class

  • 5.3 Europe

    • 5.3.1 Key trends and opportunities

    • 5.3.2 Europe Market size and forecast, by Drug Class

    • 5.3.3 Europe Market size and forecast, by country

      • 5.3.3.1 Germany

      • 5.3.3.1.1 Market size and forecast, by Drug Class

      • 5.3.3.2 France

      • 5.3.3.2.1 Market size and forecast, by Drug Class

      • 5.3.3.3 United Kingdom

      • 5.3.3.3.1 Market size and forecast, by Drug Class

      • 5.3.3.4 Italy

      • 5.3.3.4.1 Market size and forecast, by Drug Class

      • 5.3.3.5 Rest of Europe

      • 5.3.3.5.1 Market size and forecast, by Drug Class

  • 5.4 Asia-Pacific

    • 5.4.1 Key trends and opportunities

    • 5.4.2 Asia-Pacific Market size and forecast, by Drug Class

    • 5.4.3 Asia-Pacific Market size and forecast, by country

      • 5.4.3.1 Japan

      • 5.4.3.1.1 Market size and forecast, by Drug Class

      • 5.4.3.2 China

      • 5.4.3.2.1 Market size and forecast, by Drug Class

      • 5.4.3.3 Australia

      • 5.4.3.3.1 Market size and forecast, by Drug Class

      • 5.4.3.4 India

      • 5.4.3.4.1 Market size and forecast, by Drug Class

      • 5.4.3.5 Rest of Asia-Pacific

      • 5.4.3.5.1 Market size and forecast, by Drug Class

  • 5.5 LAMEA

    • 5.5.1 Key trends and opportunities

    • 5.5.2 LAMEA Market size and forecast, by Drug Class

    • 5.5.3 LAMEA Market size and forecast, by country

      • 5.5.3.1 Brazil

      • 5.5.3.1.1 Market size and forecast, by Drug Class

      • 5.5.3.2 Turkey

      • 5.5.3.2.1 Market size and forecast, by Drug Class

      • 5.5.3.3 South Africa

      • 5.5.3.3.1 Market size and forecast, by Drug Class

      • 5.5.3.4 Rest of LAMEA

      • 5.5.3.4.1 Market size and forecast, by Drug Class

• CHAPTER 6: COMPANY LANDSCAPE

  • 6.1. Introduction

  • 6.2. Top winning strategies

  • 6.3. Product Mapping of Top 10 Player

  • 6.4. Competitive Dashboard

  • 6.5. Competitive Heatmap

  • 6.6. Key developments

• CHAPTER 7: COMPANY PROFILES

  • 7.1 Azurity Pharmaceuticals

    • 7.1.1 Company overview

    • 7.1.2 Company snapshot

    • 7.1.3 Operating business segments

    • 7.1.4 Product portfolio

    • 7.1.5 Business performance

    • 7.1.6 Key strategic moves and developments

  • 7.2 Johnson and Johnson

    • 7.2.1 Company overview

    • 7.2.2 Company snapshot

    • 7.2.3 Operating business segments

    • 7.2.4 Product portfolio

    • 7.2.5 Business performance

    • 7.2.6 Key strategic moves and developments

  • 7.3 medicure

    • 7.3.1 Company overview

    • 7.3.2 Company snapshot

    • 7.3.3 Operating business segments

    • 7.3.4 Product portfolio

    • 7.3.5 Business performance

    • 7.3.6 Key strategic moves and developments

  • 7.4 NeurOp

    • 7.4.1 Company overview

    • 7.4.2 Company snapshot

    • 7.4.3 Operating business segments

    • 7.4.4 Product portfolio

    • 7.4.5 Business performance

    • 7.4.6 Key strategic moves and developments

  • 7.5 orexo ab

    • 7.5.1 Company overview

    • 7.5.2 Company snapshot

    • 7.5.3 Operating business segments

    • 7.5.4 Product portfolio

    • 7.5.5 Business performance

    • 7.5.6 Key strategic moves and developments

  • 7.6 Pfizer, Inc.

    • 7.6.1 Company overview

    • 7.6.2 Company snapshot

    • 7.6.3 Operating business segments

    • 7.6.4 Product portfolio

    • 7.6.5 Business performance

    • 7.6.6 Key strategic moves and developments

  • 7.7 Pharmaxis, Ltd.

    • 7.7.1 Company overview

    • 7.7.2 Company snapshot

    • 7.7.3 Operating business segments

    • 7.7.4 Product portfolio

    • 7.7.5 Business performance

    • 7.7.6 Key strategic moves and developments

  • 7.8 Sun Pharmaceutical Industries Ltd.

    • 7.8.1 Company overview

    • 7.8.2 Company snapshot

    • 7.8.3 Operating business segments

    • 7.8.4 Product portfolio

    • 7.8.5 Business performance

    • 7.8.6 Key strategic moves and developments

  • 7.9 teva pharmaceutical industries ltd.

    • 7.9.1 Company overview

    • 7.9.2 Company snapshot

    • 7.9.3 Operating business segments

    • 7.9.4 Product portfolio

    • 7.9.5 Business performance

    • 7.9.6 Key strategic moves and developments

  • 7.10 Vitrais, Inc

    • 7.10.1 Company overview

    • 7.10.2 Company snapshot

    • 7.10.3 Operating business segments

    • 7.10.4 Product portfolio

    • 7.10.5 Business performance

    • 7.10.6 Key strategic moves and developments

• LIST OF TABLES

• TABLE 1. GLOBAL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
  TABLE 2. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OPIOID ANALGESIC, BY REGION , 2020-2030,($MILLION)
  TABLE 3. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OPIOID ANALGESIC BY COUNTRY, 2020-2030,($MILLION)
  TABLE 4. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR CALCIUM CHANNEL BLOCKER, BY REGION , 2020-2030,($MILLION)
  TABLE 5. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET CALCIUM CHANNEL BLOCKER BY COUNTRY, 2020-2030,($MILLION)
  TABLE 6. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR ANTICONVULSANT, BY REGION , 2020-2030,($MILLION)
  TABLE 7. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET ANTICONVULSANT BY COUNTRY, 2020-2030,($MILLION)
  TABLE 8. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR STOOL SOFTENER, BY REGION , 2020-2030,($MILLION)
  TABLE 9. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET STOOL SOFTENER BY COUNTRY, 2020-2030,($MILLION)
  TABLE 10. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OSMOTIC AGENTS/DIURETICS, BY REGION , 2020-2030,($MILLION)
  TABLE 11. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OSMOTIC AGENTS/DIURETICS BY COUNTRY, 2020-2030,($MILLION)
  TABLE 12. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OTHER DRUGS, BY REGION , 2020-2030,($MILLION)
  TABLE 13. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OTHER DRUGS BY COUNTRY, 2020-2030,($MILLION)
  TABLE 14. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION, 2020-2030,($MILLION)
  TABLE 15. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
  TABLE 16. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 17. U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 18. CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 19. MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 20. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
  TABLE 21. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 22. GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 23. FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 24. UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 25. ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 26. REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 27. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
  TABLE 28. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 29. JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 30. CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 31. AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 32. INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 33. REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 34. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
  TABLE 35. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 36. BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 37. TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 38. SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 39. REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
  TABLE 40.AZURITY PHARMACEUTICALS: COMPANY SNAPSHOT
  TABLE 41.AZURITY PHARMACEUTICALS: OPERATING SEGMENTS
  TABLE 42.AZURITY PHARMACEUTICALS: PRODUCT PORTFOLIO
  TABLE 43.AZURITY PHARMACEUTICALS: NET SALES,
  TABLE 44.AZURITY PHARMACEUTICALS: KEY STRATERGIES
  TABLE 45.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  TABLE 46.JOHNSON AND JOHNSON: OPERATING SEGMENTS
  TABLE 47.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  TABLE 48.JOHNSON AND JOHNSON: NET SALES,
  TABLE 49.JOHNSON AND JOHNSON: KEY STRATERGIES
  TABLE 50.MEDICURE: COMPANY SNAPSHOT
  TABLE 51.MEDICURE: OPERATING SEGMENTS
  TABLE 52.MEDICURE: PRODUCT PORTFOLIO
  TABLE 53.MEDICURE: NET SALES,
  TABLE 54.MEDICURE: KEY STRATERGIES
  TABLE 55.NEUROP: COMPANY SNAPSHOT
  TABLE 56.NEUROP: OPERATING SEGMENTS
  TABLE 57.NEUROP: PRODUCT PORTFOLIO
  TABLE 58.NEUROP: NET SALES,
  TABLE 59.NEUROP: KEY STRATERGIES
  TABLE 60.OREXO AB: COMPANY SNAPSHOT
  TABLE 61.OREXO AB: OPERATING SEGMENTS
  TABLE 62.OREXO AB: PRODUCT PORTFOLIO
  TABLE 63.OREXO AB: NET SALES,
  TABLE 64.OREXO AB: KEY STRATERGIES
  TABLE 65.PFIZER, INC.: COMPANY SNAPSHOT
  TABLE 66.PFIZER, INC.: OPERATING SEGMENTS
  TABLE 67.PFIZER, INC.: PRODUCT PORTFOLIO
  TABLE 68.PFIZER, INC.: NET SALES,
  TABLE 69.PFIZER, INC.: KEY STRATERGIES
  TABLE 70.PHARMAXIS, LTD.: COMPANY SNAPSHOT
  TABLE 71.PHARMAXIS, LTD.: OPERATING SEGMENTS
  TABLE 72.PHARMAXIS, LTD.: PRODUCT PORTFOLIO
  TABLE 73.PHARMAXIS, LTD.: NET SALES,
  TABLE 74.PHARMAXIS, LTD.: KEY STRATERGIES
  TABLE 75.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  TABLE 76.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  TABLE 77.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  TABLE 78.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  TABLE 79.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  TABLE 80.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  TABLE 81.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  TABLE 82.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  TABLE 83.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  TABLE 84.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  TABLE 85.VITRAIS, INC: COMPANY SNAPSHOT
  TABLE 86.VITRAIS, INC: OPERATING SEGMENTS
  TABLE 87.VITRAIS, INC: PRODUCT PORTFOLIO
  TABLE 88.VITRAIS, INC: NET SALES,
  TABLE 89.VITRAIS, INC: KEY STRATERGIES

• LIST OF FIGURES

• FIGURE 1.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET SEGMENTATION
  FIGURE 2.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030
  FIGURE 3.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030
  FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  FIGURE 5.PORTER FIVE-1
  FIGURE 6.PORTER FIVE-2
  FIGURE 7.PORTER FIVE-3
  FIGURE 8.PORTER FIVE-4
  FIGURE 9.PORTER FIVE-5
  FIGURE 10.TOP PLAYER POSITIONING
  FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,BY DRUG CLASS,2020(%)
  FIGURE 12.COMPARATIVE SHARE ANALYSIS OF OPIOID ANALGESIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
  FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CALCIUM CHANNEL BLOCKER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
  FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTICONVULSANT ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
  FIGURE 15.COMPARATIVE SHARE ANALYSIS OF STOOL SOFTENER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
  FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OSMOTIC AGENTS/DIURETICS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
  FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER DRUGS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
  FIGURE 18.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY REGION,2020
  FIGURE 19.U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 20.CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 21.MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 22.GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 23.FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 24.UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 25.ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 26.REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 27.JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 28.CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 29.AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 30.INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 31.REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 32.BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 33.TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 34.SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 35.REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
  FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
  FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
  FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
  FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
  FIGURE 40.COMPETITIVE DASHBOARD
  FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  FIGURE 42.AZURITY PHARMACEUTICALS.: NET SALES ,($MILLION)
  FIGURE 43.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
  FIGURE 44.MEDICURE.: NET SALES ,($MILLION)
  FIGURE 45.NEUROP.: NET SALES ,($MILLION)
  FIGURE 46.OREXO AB.: NET SALES ,($MILLION)
  FIGURE 47.PFIZER, INC..: NET SALES ,($MILLION)
  FIGURE 48.PHARMAXIS, LTD..: NET SALES ,($MILLION)
  FIGURE 49.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
  FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
  FIGURE 51.VITRAIS, INC.: NET SALES ,($MILLION)